Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology

Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer

Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival

Zenex Animal Health makes strategic European play with VievePharm acquisition

VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets

Glenmark Pharmaceuticals USA to launch sodium phosphates injection

The product addresses a market with approximately $66.8 million in annual sales as of December 2025.

Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access

Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy

FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy

Synthekine teams up with Merck to test breakthrough lung cancer combo

The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk

Eugia Pharma receives USFDA Approval for Everolimus tablets

Volta Labs unveils push-button PCR-free whole genome sequencing kit

The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform